AVXL
Price
$8.79
Change
+$0.18 (+2.09%)
Updated
Oct 14 closing price
Capitalization
755.44M
68 days until earnings call
Intraday Buy/Sell Signals
SYRE
Price
$21.00
Change
+$2.08 (+10.99%)
Updated
Oct 14 closing price
Capitalization
1.27B
22 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

AVXL vs SYRE

Header iconAVXL vs SYRE Comparison
Open Charts AVXL vs SYREBanner chart's image
Anavex Life Sciences
Price$8.79
Change+$0.18 (+2.09%)
Volume$1.11M
Capitalization755.44M
Spyre Therapeutics
Price$21.00
Change+$2.08 (+10.99%)
Volume$5.56M
Capitalization1.27B
AVXL vs SYRE Comparison Chart in %
AVXL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AVXL vs. SYRE commentary
Oct 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVXL is a Hold and SYRE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 15, 2025
Stock price -- (AVXL: $8.62 vs. SYRE: $21.00)
Brand notoriety: AVXL and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AVXL: 196% vs. SYRE: 766%
Market capitalization -- AVXL: $740.4M vs. SYRE: $1.27B
AVXL [@Biotechnology] is valued at $740.4M. SYRE’s [@Biotechnology] market capitalization is $1.27B. The market cap for tickers in the [@Biotechnology] industry ranges from $104.45B to $0. The average market capitalization across the [@Biotechnology] industry is $2.07B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AVXL’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • AVXL’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, AVXL is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AVXL’s TA Score shows that 4 TA indicator(s) are bullish while SYRE’s TA Score has 6 bullish TA indicator(s).

  • AVXL’s TA Score: 4 bullish, 4 bearish.
  • SYRE’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, SYRE is a better buy in the short-term than AVXL.

Price Growth

AVXL (@Biotechnology) experienced а -10.30% price change this week, while SYRE (@Biotechnology) price change was +31.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.86%. For the same industry, the average monthly price growth was +14.21%, and the average quarterly price growth was +268.76%.

Reported Earning Dates

AVXL is expected to report earnings on Dec 22, 2025.

SYRE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+0.86% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($1.27B) has a higher market cap than AVXL($755M). SYRE YTD gains are higher at: -9.794 vs. AVXL (-18.110). AVXL has higher annual earnings (EBITDA): -45.88M vs. SYRE (-222.15M). SYRE has more cash in the bank: 527M vs. AVXL (101M). SYRE has less debt than AVXL: SYRE (0) vs AVXL (88.2K). AVXL (0) and SYRE (0) have equivalent revenues.
AVXLSYREAVXL / SYRE
Capitalization755M1.27B60%
EBITDA-45.88M-222.15M21%
Gain YTD-18.110-9.794185%
P/E RatioN/A1.68-
Revenue00-
Total Cash101M527M19%
Total Debt88.2K0-
FUNDAMENTALS RATINGS
AVXL vs SYRE: Fundamental Ratings
AVXL
SYRE
OUTLOOK RATING
1..100
1675
VALUATION
overvalued / fair valued / undervalued
1..100
49
Fair valued
66
Overvalued
PROFIT vs RISK RATING
1..100
80100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
4760
P/E GROWTH RATING
1..100
10084
SEASONALITY SCORE
1..100
8528

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AVXL's Valuation (49) in the Biotechnology industry is in the same range as SYRE (66) in the Pharmaceuticals Major industry. This means that AVXL’s stock grew similarly to SYRE’s over the last 12 months.

AVXL's Profit vs Risk Rating (80) in the Biotechnology industry is in the same range as SYRE (100) in the Pharmaceuticals Major industry. This means that AVXL’s stock grew similarly to SYRE’s over the last 12 months.

AVXL's SMR Rating (97) in the Biotechnology industry is in the same range as SYRE (98) in the Pharmaceuticals Major industry. This means that AVXL’s stock grew similarly to SYRE’s over the last 12 months.

AVXL's Price Growth Rating (47) in the Biotechnology industry is in the same range as SYRE (60) in the Pharmaceuticals Major industry. This means that AVXL’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's P/E Growth Rating (84) in the Pharmaceuticals Major industry is in the same range as AVXL (100) in the Biotechnology industry. This means that SYRE’s stock grew similarly to AVXL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AVXLSYRE
RSI
ODDS (%)
N/A
Bullish Trend 7 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 7 days ago
74%
Bearish Trend 7 days ago
88%
Momentum
ODDS (%)
Bullish Trend 7 days ago
73%
Bullish Trend 7 days ago
84%
MACD
ODDS (%)
Bullish Trend 7 days ago
82%
Bullish Trend 7 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 7 days ago
83%
Bullish Trend 7 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 7 days ago
83%
Bullish Trend 7 days ago
82%
Advances
ODDS (%)
Bullish Trend 7 days ago
79%
Bullish Trend 15 days ago
84%
Declines
ODDS (%)
Bearish Trend 21 days ago
81%
Bearish Trend 12 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 7 days ago
76%
Bearish Trend 7 days ago
90%
Aroon
ODDS (%)
Bearish Trend 7 days ago
78%
Bearish Trend 7 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
AVXL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EQNRX23.580.24
+1.03%
MFS Equity Income R1
BHEIX29.190.25
+0.86%
BlackRock High Equity Income K
MTRRX20.290.10
+0.50%
MFS Total Return R2
ISGNX17.00N/A
N/A
Columbia Integrated Small Cap Gr Instl
AIGGX17.55-0.18
-1.02%
Aristotle Growth Equity I-2

AVXL and

Correlation & Price change

A.I.dvisor indicates that over the last year, AVXL has been loosely correlated with PLRX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if AVXL jumps, then PLRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AVXL
1D Price
Change %
AVXL100%
+2.03%
PLRX - AVXL
47%
Loosely correlated
+1.34%
TENX - AVXL
45%
Loosely correlated
+1.35%
RXRX - AVXL
40%
Loosely correlated
+6.51%
SYRE - AVXL
37%
Loosely correlated
+11.02%
TRAW - AVXL
37%
Loosely correlated
+1.72%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with VRDN. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then VRDN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
+11.02%
VRDN - SYRE
58%
Loosely correlated
-2.76%
CGON - SYRE
58%
Loosely correlated
-0.26%
IDYA - SYRE
57%
Loosely correlated
+1.12%
XNCR - SYRE
56%
Loosely correlated
-10.96%
APGE - SYRE
56%
Loosely correlated
-2.96%
More